{"protocolSection": {"identificationModule": {"nctId": "NCT01350414", "orgStudyIdInfo": {"id": "10-01"}, "organization": {"fullName": "Boston Scientific Corporation", "class": "INDUSTRY"}, "briefTitle": "AIR2 Extension Study to Demonstrate Longer-term (> 1 Year) Durability of Effectiveness", "officialTitle": "AIR2 Extension Study to Demonstrate Longer-term (> 1 Year) Durability of Effectiveness", "acronym": "PAS1"}, "statusModule": {"statusVerifiedDate": "2016-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2005-10"}, "primaryCompletionDateStruct": {"date": "2012-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2012-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-10-28", "studyFirstSubmitQcDate": "2011-05-06", "studyFirstPostDateStruct": {"date": "2011-05-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-06-17", "resultsFirstSubmitQcDate": "2016-08-03", "resultsFirstPostDateStruct": {"date": "2016-09-26", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2016-08-03", "lastUpdatePostDateStruct": {"date": "2016-09-26", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boston Scientific Corporation", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The objective of this study is to evaluate durability of effectiveness (beyond one year) of the Alair System in patients with severe persistent asthma. The study will consist of Alair-group subjects who are currently in the follow-up phase (out to 5 years) of the AIR2 Trial (Protocol #04-02, clinicaltrials.gov number NCT00231114).\n\nDurability of the treatment effect will be evaluated by comparing the proportion of subjects who experience severe exacerbations during the first year after Alair treatment with the proportion of subjects who experience severe exacerbations during subsequent 12 month periods out to 5 years.\n\nAll Alair group subjects in the AIR2 Trial are being followed out to 5 years as per the AIR2 Trial protocol. The data that are to be used to determine durability of effectiveness as described in the present protocol (Protocol #10-01) are being collected under the existing AIR2 Trial protocol (Protocol # 04-02).\n\nStudy Hypothesis: An empirical demonstration of the durability of the treatment effect will be used to show that the proportion of subjects experiencing severe exacerbations for the first year compared with the proportions of subjects experiencing severe exacerbations in subsequent years do not get substantially worse.\n\nThe primary statistical objective is to demonstrate that the proportion of subjects who experience severe exacerbations in the subsequent 12-month follow-up (for Year 2, Year 3, Year 4 and Year 5 \\[in 12-month periods\\]) is not statistically worse when compared with the proportion of first 12-months, which begins 6-weeks after the last Alair treatment. This objective will be met if the upper 95% confidence limit of the difference in proportions (i.e., the subsequent 12-month proportion minus the first 12-month proportion) is less than 20%.", "detailedDescription": "This will be an open-label, single arm study designed to demonstrate the durability of effectiveness (beyond one year) of the Alair System in patients with severe persistent asthma.\n\nDurability of treatment effect will be evaluated by comparison of the proportion of subjects experiencing severe exacerbations during the first year after the Alair treatment to subsequent 12-month periods out to 5 years.\n\nThe 12-month periods will begin 6 weeks post-last Alair bronchoscopy."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "COHORT", "timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 181, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114)", "interventionNames": ["Device: Bronchial Thermoplasty with the Alair System"]}], "interventions": [{"type": "DEVICE", "name": "Bronchial Thermoplasty with the Alair System", "description": "Bronchial Thermoplasty with the Alair System", "armGroupLabels": ["Alair Group"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Severe Exacerbations", "description": "The primary endpoint will be the proportion of subjects experiencing severe exacerbations during the first year after the Alair treatment compared to subsequent 12-month periods out to 5 years. This objective will be met if the upper 95% confidence limit of the difference in proportions (i.e., the subsequent 12-month proportion minus the first 12-month proportion) is less than 20%.\n\nSevere exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02).", "timeFrame": "12 month periods out to 5 Years"}], "secondaryOutcomes": [{"measure": "Severe Exacerbations", "description": "Number of severe exacerbations per subject per year. Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02).", "timeFrame": "12 Month periods out to 5 years"}, {"measure": "Respiratory Adverse Events", "description": "Number of respiratory adverse events per subject per year. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the \"Respiratory System\" that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.", "timeFrame": "12 Month periods out to 5 years"}, {"measure": "Respiratory Adverse Events", "description": "Proportion of subjects experiencing one or more respiratory adverse event in each of the years 1 through 5 following the Alair treatment. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the \"Respiratory System\" that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.", "timeFrame": "12 Month periods out to 5 years"}, {"measure": "Emergency Room Visits for Respiratory Symptoms", "description": "Proportion of Subjects with Emergency Room Visits for Respiratory Symptoms", "timeFrame": "12 Month periods out to 5 years"}, {"measure": "Emergency Room (ER) Visits for Respiratory Symptoms", "description": "Number of Emergency Room Visits for Respiratory Symptoms per subject per year.", "timeFrame": "12 Month periods out to 5 years"}, {"measure": "Hospitalizations for Respiratory Symptoms", "description": "Proportion of subjects with hospitalizations for respiratory symptoms.", "timeFrame": "12 Month periods out to 5 Years"}, {"measure": "Hospitalizations for Respiratory Symptoms", "description": "Number of Hospitalizations for Respiratory Symptoms per subject per year.", "timeFrame": "12 Month periods out to 5 years"}, {"measure": "Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", "description": "Pre-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5.", "timeFrame": "12 Month periods out to 5 years"}, {"measure": "Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", "description": "Post-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5.", "timeFrame": "12 Month periods out to 5 years"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* All Alair group subjects who have participated in the AIR2 Trial (NCT00231114) and were not lost to follow-up at the end of the 12 month premarket visit, and those who are willing to comply with the study protocol and routine visits for the duration of the study will be included in the post-approval study\n\nExclusion Criteria:\n\n* None.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "All Alair group subjects who have participated in the AIR2 Trial (NCT00231114) and were not lost to follow-up at the end of the 12 month premarket visit, and those who are willing to comply with the study protocol and routine visits for the duration of the study will be included in the post-approval study.", "samplingMethod": "NON_PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Narinder S Shargill, PhD", "affiliation": "Asthmatx, Inc.", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "19815809", "type": "BACKGROUND", "citation": "Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, Barbers R, Ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G; AIR2 Trial Study Group. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24. doi: 10.1164/rccm.200903-0354OC. Epub 2009 Oct 8."}, {"pmid": "23998657", "type": "RESULT", "citation": "Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, Fiss E, Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Hales JB, McEvoy C, Slebos DJ, Holmes M, Phillips MJ, Erzurum SC, Hanania NA, Sumino K, Kraft M, Cox G, Sterman DH, Hogarth K, Kline JN, Mansur AH, Louie BE, Leeds WM, Barbers RG, Austin JH, Shargill NS, Quiring J, Armstrong B, Castro M; Asthma Intervention Research 2 Trial Study Group. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013 Dec;132(6):1295-302. doi: 10.1016/j.jaci.2013.08.009. Epub 2013 Aug 30."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02)\n\nBronchial Thermoplasty with the Alair System: Bronchial Thermoplasty with the Alair System"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "181"}]}, {"type": "Year 2", "achievements": [{"groupId": "FG000", "numSubjects": "165"}]}, {"type": "Year 3", "achievements": [{"groupId": "FG000", "numSubjects": "162"}]}, {"type": "Year 4", "achievements": [{"groupId": "FG000", "numSubjects": "159"}]}, {"type": "Year 5", "achievements": [{"groupId": "FG000", "numSubjects": "162"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "162"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "13"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "AIR2 Extension Subjects Completing Follow-up at Year 1", "groups": [{"id": "BG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02, NCT00231114)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "181"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.8", "spread": "11.81"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "102"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "79"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Brazil", "categories": [{"measurements": [{"groupId": "BG000", "value": "54"}]}]}, {"title": "Canada", "categories": [{"measurements": [{"groupId": "BG000", "value": "34"}]}]}, {"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "54"}]}]}, {"title": "Australia", "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}]}]}, {"title": "United Kingdom", "categories": [{"measurements": [{"groupId": "BG000", "value": "27"}]}]}, {"title": "Netherlands", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}]}]}]}, {"title": "Height (cm)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "166.8", "spread": "8.94"}]}]}]}, {"title": "Weight (kg)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "81.9", "spread": "17.95"}]}]}]}, {"title": "ICS Dose (Inhaled Corticosteroid dose)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mcg/day (micrograms/day)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "1943.9", "spread": "722.39"}]}]}]}, {"title": "LABA Dose (Long-acting Beta Agonists)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mcg/day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "119.2", "spread": "45.64"}]}]}]}, {"title": "OCS Dose (Oral corticosteroids)", "description": "This measure includes only 7 participants using OCS at baseline.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/day", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "6.4", "spread": "1.97"}]}]}]}, {"title": "Asthma Quality of Life Questionnaire (AQLQ) Score", "description": "There are 32 questions in the AQLQ and they are in 4 domains (symptoms, activity limitation, emotional function and environmental stimuli). Patients are asked to think about how they have been during the previous two weeks and to respond to each of the 32 questions on a 7-point scale (7 = not impaired at all - 1 = severely impaired). The overall AQLQ score is the mean of all 32 responses and the individual domain scores are the means of the items in those domains.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Scores on a scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "4.32", "spread": "1.15"}]}]}]}, {"title": "Pre-Bronchodilator FEV1 (Forced Expiratory Volume in 1 second)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "77.8", "spread": "15.67"}]}]}]}, {"title": "Post-Bronchodilator FEV1 (Forced Expiratory Volume in 1 second)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% predicted", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "86", "spread": "15.65"}]}]}]}, {"title": "amPEF (Peak Expiratory Flow)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "L/min (liters per minute)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "383.4", "spread": "104.65"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Severe Exacerbations", "description": "The primary endpoint will be the proportion of subjects experiencing severe exacerbations during the first year after the Alair treatment compared to subsequent 12-month periods out to 5 years. This objective will be met if the upper 95% confidence limit of the difference in proportions (i.e., the subsequent 12-month proportion minus the first 12-month proportion) is less than 20%.\n\nSevere exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02).", "populationDescription": "Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage subjects severe exacerbations", "timeFrame": "12 month periods out to 5 Years", "groups": [{"id": "OG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "30.9", "lowerLimit": "24.2", "upperLimit": "37.7"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.6", "lowerLimit": "17.2", "upperLimit": "30.1"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "34", "lowerLimit": "26.7", "upperLimit": "41.2"}]}]}, {"title": "Year 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "36.5", "lowerLimit": "29", "upperLimit": "44"}]}]}, {"title": "Year 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "21.6", "lowerLimit": "15.3", "upperLimit": "27.9"}]}]}]}, {"type": "SECONDARY", "title": "Severe Exacerbations", "description": "Number of severe exacerbations per subject per year. Severe exacerbation is defined as treatment with oral or intravenous corticosteroids, OR a doubling of the baseline inhaled corticosteroid dose for at least 3 days, OR any temporary increase in the dosage of oral corticosteroids for a subject taking maintenance oral corticosteroids at entry into the AIR2 Trial (Protocol #04-02).", "populationDescription": "Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Number of events/Number of subjects/Year", "timeFrame": "12 Month periods out to 5 years", "groups": [{"id": "OG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.486", "lowerLimit": "0.385", "upperLimit": "0.614"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.406", "lowerLimit": "0.311", "upperLimit": "0.531"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.549", "lowerLimit": "0.435", "upperLimit": "0.693"}]}]}, {"title": "Year 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.560", "lowerLimit": "0.444", "upperLimit": "0.706"}]}]}, {"title": "Year 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.309", "lowerLimit": "0.226", "upperLimit": "0.421"}]}]}]}, {"type": "SECONDARY", "title": "Respiratory Adverse Events", "description": "Number of respiratory adverse events per subject per year. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the \"Respiratory System\" that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.", "populationDescription": "Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Number of events/number of subject/Year", "timeFrame": "12 Month periods out to 5 years", "groups": [{"id": "OG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.022", "lowerLimit": "1.764", "upperLimit": "2.318"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.218", "lowerLimit": "1.013", "upperLimit": "1.465"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.247", "lowerLimit": "1.037", "upperLimit": "1.499"}]}]}, {"title": "Year 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.176", "lowerLimit": "0.971", "upperLimit": "1.424"}]}]}, {"title": "Year 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.778", "lowerLimit": "0.616", "upperLimit": "0.982"}]}]}]}, {"type": "SECONDARY", "title": "Respiratory Adverse Events", "description": "Proportion of subjects experiencing one or more respiratory adverse event in each of the years 1 through 5 following the Alair treatment. A respiratory adverse event is defined as any sign, symptom, illness, clinically significant abnormal laboratory value, or other adverse medical event associated with the \"Respiratory System\" that appears or worsens in a subject during a clinical study, regardless of whether or not it is considered related to the procedure used as part of the protocol.", "populationDescription": "Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage subjects with respiratory AE", "timeFrame": "12 Month periods out to 5 years", "groups": [{"id": "OG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "72.9", "lowerLimit": "66.5", "upperLimit": "79.4"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "58.8", "lowerLimit": "51.3", "upperLimit": "66.3"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "58", "lowerLimit": "50.4", "upperLimit": "65.6"}]}]}, {"title": "Year 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "54.7", "lowerLimit": "47", "upperLimit": "62.5"}]}]}, {"title": "Year 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "47.5", "lowerLimit": "39.8", "upperLimit": "55.2"}]}]}]}, {"type": "SECONDARY", "title": "Emergency Room Visits for Respiratory Symptoms", "description": "Proportion of Subjects with Emergency Room Visits for Respiratory Symptoms", "populationDescription": "Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage subjects ER respir. symptoms", "timeFrame": "12 Month periods out to 5 years", "groups": [{"id": "OG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "5", "lowerLimit": "1.8", "upperLimit": "8.1"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.7", "lowerLimit": "2.9", "upperLimit": "10.5"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "8", "lowerLimit": "3.8", "upperLimit": "12.2"}]}]}, {"title": "Year 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.9", "lowerLimit": "3", "upperLimit": "10.9"}]}]}, {"title": "Year 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.6", "lowerLimit": "2", "upperLimit": "9.1"}]}]}]}, {"type": "SECONDARY", "title": "Emergency Room (ER) Visits for Respiratory Symptoms", "description": "Number of Emergency Room Visits for Respiratory Symptoms per subject per year.", "populationDescription": "Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Number of events/subject/year", "timeFrame": "12 Month periods out to 5 years", "groups": [{"id": "OG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.072", "lowerLimit": "0.048", "upperLimit": "0.107"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.085", "lowerLimit": "0.058", "upperLimit": "0.124"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.136", "lowerLimit": "0.100", "upperLimit": "0.184"}]}]}, {"title": "Year 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.094", "lowerLimit": "0.065", "upperLimit": "0.136"}]}]}, {"title": "Year 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.068", "lowerLimit": "0.044", "upperLimit": "0.104"}]}]}]}, {"type": "SECONDARY", "title": "Hospitalizations for Respiratory Symptoms", "description": "Proportion of subjects with hospitalizations for respiratory symptoms.", "populationDescription": "Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of subjects hospitalized", "timeFrame": "12 Month periods out to 5 Years", "groups": [{"id": "OG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.3", "lowerLimit": "0.7", "upperLimit": "5.9"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "4.2", "lowerLimit": "1.2", "upperLimit": "7.3"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.2", "lowerLimit": "2.5", "upperLimit": "9.9"}]}]}, {"title": "Year 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "5.7", "lowerLimit": "2.1", "upperLimit": "9.3"}]}]}, {"title": "Year 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.9", "lowerLimit": "0.0", "upperLimit": "3.9"}]}]}]}, {"type": "SECONDARY", "title": "Hospitalizations for Respiratory Symptoms", "description": "Number of Hospitalizations for Respiratory Symptoms per subject per year.", "populationDescription": "Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.", "reportingStatus": "POSTED", "paramType": "NUMBER", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Number of events/subjects/year", "timeFrame": "12 Month periods out to 5 years", "groups": [{"id": "OG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.039", "lowerLimit": "0.025", "upperLimit": "0.060"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.061", "lowerLimit": "0.042", "upperLimit": "0.087"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.068", "lowerLimit": "0.048", "upperLimit": "0.096"}]}]}, {"title": "Year 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.075", "lowerLimit": "0.054", "upperLimit": "0.105"}]}]}, {"title": "Year 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.025", "lowerLimit": "0.014", "upperLimit": "0.044"}]}]}]}, {"type": "SECONDARY", "title": "Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", "description": "Pre-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5.", "populationDescription": "Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of change from Baseline", "timeFrame": "12 Month periods out to 5 years", "groups": [{"id": "OG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol number 04-02, NCT00231114)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.4", "spread": "14.82"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4.6", "spread": "15.36"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.7", "spread": "15.33"}]}]}, {"title": "Year 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "14.60"}]}]}, {"title": "Year 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "-1.2", "spread": "16.33"}]}]}]}, {"type": "SECONDARY", "title": "Post-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)", "description": "Post-Bronchodilator FEV1 (% Predicted) percentage changes from Baseline to the Year 1, Year 2, Year 3, Year 4, and Year 5.", "populationDescription": "Number of Subjects Completing Follow-up. 181 subjects completed 12 month follow-up; 165 subjects completed Year 2 follow-up; 162 subjects completed Year 3 follow-up; 159 subjects completed Year 4 follow-up; and 162 subjects completed Year 5 follow-up.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Percentage of change from Baseline", "timeFrame": "12 Month periods out to 5 years", "groups": [{"id": "OG000", "title": "Alair Group", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol Number 04-02, NCT00231114)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "181"}]}], "classes": [{"title": "Year 1", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.8", "spread": "10.67"}]}]}, {"title": "Year 2", "categories": [{"measurements": [{"groupId": "OG000", "value": "-5.4", "spread": "11.51"}]}]}, {"title": "Year 3", "categories": [{"measurements": [{"groupId": "OG000", "value": "-4", "spread": "12.88"}]}]}, {"title": "Year 4", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.7", "spread": "11.65"}]}]}, {"title": "Year 5", "categories": [{"measurements": [{"groupId": "OG000", "value": "-3.8", "spread": "11.95"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "12 months out to 5 years", "description": "In previous outcome analysis and in the participant flow, the denominator was based on the number of subjects that completed the corresponding annual visit. For Adverse Events the denominator was based on all the subjects that entered that period regardless of whether they completed the annual visit or not for that period.", "eventGroups": [{"id": "EG000", "title": "Year 1", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).\n\nYear 1 is defined as 365 days from the treatment period (6 weeks after the last bronchoscopy). All subjects were considered in the analysis regardless of whether they have completed the Year 1 annual visit or not.", "seriousNumAffected": 5, "seriousNumAtRisk": 187, "otherNumAffected": 112, "otherNumAtRisk": 187}, {"id": "EG001", "title": "Year 2", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).\n\nYear 2 is defined as 366 to 730 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 2 annual visit or not.", "seriousNumAffected": 8, "seriousNumAtRisk": 168, "otherNumAffected": 89, "otherNumAtRisk": 168}, {"id": "EG002", "title": "Year 3", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).\n\nYear 3 is defined as 731 to 1095 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 3 annual visit or not.", "seriousNumAffected": 10, "seriousNumAtRisk": 163, "otherNumAffected": 81, "otherNumAtRisk": 163}, {"id": "EG003", "title": "Year 4", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).\n\nYear 4 is defined as 1096 to 1460 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 4 annual visit or not.", "seriousNumAffected": 9, "seriousNumAtRisk": 163, "otherNumAffected": 77, "otherNumAtRisk": 163}, {"id": "EG004", "title": "Year 5", "description": "Subjects who underwent treatment with the Alair System in the AIR2 Trial (Protocol No. 04-02).\n\nYear 5 is defined as 1461 days to 1826 days after the treatment period. All subjects were considered in the analysis regardless of whether they have completed the Year 5 annual visit or not.", "seriousNumAffected": 3, "seriousNumAtRisk": 162, "otherNumAffected": 61, "otherNumAtRisk": 162}], "seriousEvents": [{"term": "Angina pectoris", "organSystem": "Cardiac disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Angina unstable", "organSystem": "Cardiac disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 162}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Supraventricular tachycardia", "organSystem": "Cardiac disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Addison's disease", "organSystem": "Endocrine disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Anorectal disorder", "organSystem": "Gastrointestinal disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Haemorrhoids", "organSystem": "Gastrointestinal disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Pyrexia", "organSystem": "General disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Cholecystitis acute", "organSystem": "Hepatobiliary disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 162}]}, {"term": "Abscess limb", "organSystem": "Infections and infestations", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 162}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Cellulitis", "organSystem": "Infections and infestations", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Infective tenosynovitis", "organSystem": "Infections and infestations", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Osteomyelitis", "organSystem": "Infections and infestations", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Perianal abscess", "organSystem": "Infections and infestations", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Pyelonephritis", "organSystem": "Infections and infestations", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Viral labyrinthitis", "organSystem": "Infections and infestations", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Incisional hernia", "organSystem": "Injury, poisoning and procedural complications", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Injury", "organSystem": "Injury, poisoning and procedural complications", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 162}]}, {"term": "Traumatic brain injury", "organSystem": "Injury, poisoning and procedural complications", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Obesity", "organSystem": "Metabolism and nutrition disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Chondrocalcinosis pyrophosphate", "organSystem": "Musculoskeletal and connective tissue disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Osteonecrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Acute myeloid leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Breast cancer in situ", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Chronic myeloid leukaemia", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Pituitary tumour", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Paraesthesia", "organSystem": "Nervous system disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Abortion spontaneous", "organSystem": "Pregnancy, puerperium and perinatal conditions", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 8, "numAffected": 6, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 8, "numAffected": 7, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 9, "numAffected": 6, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 3, "numAffected": 2, "numAtRisk": 162}]}, {"term": "Bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 162}]}, {"term": "Chest pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Lobar pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Lower respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Pneumonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Sinusitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Knee arthroplasty", "organSystem": "Surgical and medical procedures", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}, {"term": "Arteriosclerosis", "organSystem": "Vascular disorders", "notes": "Non-respiratory", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 162}]}], "otherEvents": [{"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 87, "numAffected": 52, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 77, "numAffected": 47, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 82, "numAffected": 48, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 81, "numAffected": 51, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 52, "numAffected": 40, "numAtRisk": 162}]}, {"term": "Bronchitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 18, "numAffected": 14, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 14, "numAffected": 12, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 11, "numAffected": 8, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 7, "numAffected": 6, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 6, "numAffected": 5, "numAtRisk": 162}]}, {"term": "Lower respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 7, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 15, "numAffected": 9, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 14, "numAffected": 11, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 20, "numAffected": 15, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 7, "numAffected": 6, "numAtRisk": 162}]}, {"term": "Nasopharyngitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 27, "numAffected": 21, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 10, "numAffected": 9, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 7, "numAffected": 6, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 6, "numAffected": 6, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 162}]}, {"term": "Sinusitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 16, "numAffected": 12, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 17, "numAffected": 16, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 14, "numAffected": 11, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 10, "numAffected": 9, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 7, "numAffected": 6, "numAtRisk": 162}]}, {"term": "Upper respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 81, "numAffected": 57, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 29, "numAffected": 24, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 25, "numAffected": 24, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 28, "numAffected": 23, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 23, "numAffected": 18, "numAtRisk": 162}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Respiratory, thoracic and mediastinal disorders", "notes": "Respiratory", "stats": [{"groupId": "EG000", "numEvents": 12, "numAffected": 11, "numAtRisk": 187}, {"groupId": "EG001", "numEvents": 6, "numAffected": 6, "numAtRisk": 168}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 163}, {"groupId": "EG004", "numEvents": 3, "numAffected": 3, "numAtRisk": 162}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "LTE60", "restrictiveAgreement": true}, "pointOfContact": {"title": "Narinder Shargill", "organization": "Boston Scientific", "email": "Narinder.Shargill@bsci.com", "phone": "408-635-3907"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}}, "hasResults": true}